Clinical Trials · NCT06085482
A Phase I Study of LY3502970 in Healthy Participants
- Phase
- Phase 1
- Recruitment status
- Completed
- Sponsor
- Eli Lilly and Company
- Enrollment
- 10
- Start date
- Oct 2023
- Locations
- 1 site, United States
- Primary endpoint
- Pharmacokinetics (PK): Absolute Bioavailability of LY3502970